Pure Global
NCT01013285

Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center·Phase 2·ClinicalTrials.gov·biologicalCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
bevacizumab
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Jonsson Comprehensive Cancer Center
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2006
End date
Aug 01, 2015
Enrollment
70 participants
Primary outcome

Overall Survival

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
 ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
 help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
 growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such
 as temozolomide, work in different ways to stop the growth of tumor cells, either by killing
 the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to
 kill tumor cells. Giving bevacizumab together with temozolomide and radiation therapy may
 kill more tumor cells.
 
 PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab
 together with temozolomide and external beam radiation therapy works when given as first-line
 therapy in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01013285
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01013285 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jonsson Comprehensive Cancer Center and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.